18 results about "Helicobacter pylori" patented technology

Disclosed is a composition for eradicating Helicobacter pylori, comprising zastaprazan or a pharmaceutically acceptable salt thereof.

The present application provides a compound comprising a structure shown in formula (I), and the present application also provides use of the compound for selectively inhibiting or preventing growth of Helicobacter pylori, and / or preparing a medicament.

This invention relates to the field of biomedical technology, specifically to a subspecies of Bifidobacterium animalis B189 and its applications. The classification name of this strain is... Bifidobacterium animalum subsp . animal The accession number is CGMCC No. 37052. Bifidobacterium animalis B189 not only exhibits significant antibacterial effects against Helicobacter pylori, but also possesses extremely strong acid and bile resistance, making it valuable for the development of microbial agents to inhibit Helicobacter pylori.

This invention belongs to the field of biodetection technology, specifically disclosing a primer-probe composition and kit for detecting drug-resistant gene mutations in Helicobacter pylori. The composition comprises two sets of primers and probes, using the probe melting curve method as its principle. The composition and universal PCR reagents are used to detect multiple drug resistance mutations in the quinolone resistance gene gyrA and the clarithromycin resistance gene 23S rRNA of Helicobacter pylori in biological samples. This overcomes the limitation of existing methods that only detect single mutation sites in a single tube for Helicobacter pylori drug resistance genes, providing a new, rapid, and efficient method for detecting Helicobacter pylori drug resistance genes.

This invention discloses a strain of *Lactococcus gasseri* LG3092 that produces the bacteriocin GarQ and effectively antagonizes multidrug-resistant *Helicobacter pylori*, and its applications. *Lactococcus gasseri* LG3092 was deposited at the Guangdong Provincial Microbial Culture Collection Center on October 30, 2023, with accession number GDMCC No: 63939. Studies have shown that LG3092 has the following beneficial effects: (1) it can produce the bacteriocin GarQ, effectively inhibiting the growth of *Helicobacter pylori* and other common pathogenic bacteria; (2) it has a high survival rate in the stomach, can colonize the stomach, and can compete with pathogenic bacteria for binding sites, effectively reducing the infection rate of *Helicobacter pylori* in the stomach; (3) it can improve the pathological state of the stomach and alleviate inflammation. Therefore, *Lactococcus gasseri* LG3092 has great application potential in the preparation of products for the prevention or treatment of *H. pylori*, especially multidrug-resistant *H. pylori* infection.

A Helicobacter pylori composite antigen, which is composed of full-length or partial sequences of five antigen proteins, namely urease (UreB), vacuolating cytotoxin (VacA), cytotoxin gene A (CagA), adhesin HpaA and adhesin BabA, wherein the amino acid sequences of the five antigen proteins are respectively as shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4 and SEQ ID No. 5. The composite antigen has a higher immunogenicity, and an anti-Hp egg yolk antibody prepared by the composite antigen has a higher Hp-neutralizing activity, and can efficiently block the colonization of Hp and inhibit the activity of the Hp at the same time, thereby efficiently preventing and treating gastrointestinal diseases caused by Hp infections.

: Title: Antibacterial Application of Pyrrolidin-Piperdine Derivatives Containing Composition to Inhibit Helicobacter Pylori Replication, Preparation Method Thereof The present disclosure proposes a method for identification, optimizing, and preparing a therapeutic molecule (MA01027) for inhibiting cytotoxin-associated gene A (CagA) protein of Helicobacter pylori. The therapeutic molecule specifically targets and binds to a particular protein of interest, thereby enhancing the efficacy and specificity of the treatment. The therapeutic molecule is optimized for its binding affinity and selectivity for the target protein. The therapeutic molecule involves combining specific reactants under controlled conditions to achieve high yields and purity of the therapeutic molecule. The therapeutic molecule preparation includes purification steps to isolate the therapeutic molecule from the reaction mixture using standard techniques, thereby ensuring a high-quality final product. The therapeutic molecule binds to the CagA protein of H. pylori, inhibiting its replication by more than 90% and eliminating H. pylori-associated hemolysis.

The present application relates to the technical field of probiotic composition, and discloses an anti-helicobacter pylori probiotic composition for repairing gastric mucosa and regulating intestinal flora, which comprises 35-45 parts of Lactobacillus plantarum R202448 freeze-dried powder, 20-30 parts of Weizmannia coagulans BHE26 freeze-dried powder, 15-25 parts of Lactobacillus paracasei SMN-LBK freeze-dried powder, 10-15 parts of Lactobacillus acidophilus NCFM freeze-dried powder, 5-10 parts of prebiotic compound, 2-5 parts of gastric mucosa repair enhancer and 5-10 parts of auxiliary materials. Different probiotics are fermented separately in the present application, so as to avoid the nutritional competition and metabolic antagonism of mixed fermentation, and at the same time, a compatible metabolic environment between strains is constructed in advance through metabolic adaptation liquid, so as to ensure that the synergistic effect of each strain after compounding is not weakened.

This invention discloses a portable fluorescence detection device, belonging to the field of fluorescence detection technology, suitable for rapid on-site detection of samples such as Helicobacter pylori. The device includes a 480 nm wavelength excitation LED light source, a plano-convex lens, a 480 nm wavelength filter, a 520 nm wavelength filter, a mounting base, a photodetector, a control circuit, and supporting software. The mounting base and internal optical path are made of black matte material to suppress stray light interference. The plano-convex lens and filter are fixed to the corresponding optical axis. The 480 nm wavelength excitation light, after collimation and filtering, is incident on the sample at a 45° angle, and the fluorescence is received by the detector after filtering. The control circuit integrates WIFI / Bluetooth and a serial port, which can acquire network time as a data tag and adjust the excitation light power. The software constructs a neural network detection model based on the sample dataset to achieve qualitative and quantitative detection. This device is compact and portable, with replaceable slides, and provides accurate and efficient detection, suitable for clinical and on-site screening.

The application discloses a preparation method of a bile acid-norfloxacin compound, which comprises the following steps: reacting bile acid and norfloxacin in the presence of 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate and diisopropylethylamine in THF solvent at 10-30 DEG C for 12-30 h, and then carrying out post-treatment to obtain the bile acid-norfloxacin compound. The bile acid-norfloxacin compound is obtained by condensation reaction between the carboxyl group of the bile acid and the piperazine group of the norfloxacin, and the compound structure is combined with the bile acid and the norfloxacin. The antibacterial activity of the norfloxacin is obviously improved, the norfloxacin has better inhibition effect on Escherichia coli, Helicobacter pylori and the like, and also has better inhibition effect on Pseudomonas aeruginosa, Staphylococcus aureus and Pneumococcus, and meanwhile, the preparation operation process is simple.

This invention belongs to the field of biological vaccine technology, and more specifically, relates to recombinant ferritin, vaccines, their preparation methods, and applications. The recombinant ferritin is composed of three copies of Aβ... 1‑15 The antigenic peptide is tandemly linked via a flexible linker and then inserted into the symmetry axis site (double, triple, or quadruple symmetry axis) of Helicobacter pylori ferritin using gene fusion technology. Its amino acid sequence is shown in SEQ ID NO. 5, SEQ ID NO. 6, and SEQ ID NO. 7. This invention also provides the gene encoding this recombinant ferritin, the recombinant vector, the recombinant bacteria, and a method for its preparation. A vaccine prepared using this recombinant ferritin as the active ingredient, in combination with an adjuvant, can break autoimmune tolerance in AD model mice, induce the production of high-titer specific antibodies, significantly clear Aβ deposits in the brain, and improve cognitive function, without inducing adverse reactions such as cerebral microhemorrhage. It can be used to prepare drugs for the treatment of Alzheimer's disease.

The application provides a stomach cancer risk prediction method combining PRS and Helicobacter pylori virulence factors, and belongs to the technical field of stomach cancer risk prediction, and comprises the following steps: obtaining host genetic data and Helicobacter pylori virulence factor detection data of a to-be-tested individual; calculating a stomach cancer polygene risk score PRS of the to-be-tested individual based on the host genetic data; calculating a Helicobacter pylori virulence comprehensive score VFS of the to-be-tested individual based on the Helicobacter pylori virulence factor detection data; inputting the stomach cancer polygene risk score PRS and the Helicobacter pylori virulence comprehensive score VFS into a pre-trained stomach cancer risk prediction model to obtain a stomach cancer risk prediction result of the to-be-tested individual. The stomach cancer risk prediction accuracy and high-risk population enrichment efficiency are significantly improved, the AUC of the discovery set reaches 0.765, 67% of stomach cancer cases can be identified from the Top 10% high-risk population, the method is suitable for precise screening, individualized follow-up and prevention intervention of stomach cancer of East Asian population, and has important clinical application value.

The application discloses a gastric cancer progression risk assessment system, and belongs to the technical field of bioinformatics and medical diagnosis. The system comprises a genomic data acquisition module, a core genomic variation feature construction module, a population structure correction module, a risk site identification module, a multi-site risk scoring module, a disease progression prediction module, and a risk judgment and report module. By deeply mining the core genomic information of the strain, filtering the recombination region and correcting the population structure, the strain risk sites significantly related to the progression of host gastric mucosa lesions are accurately screened, and then a risk scoring model is constructed, so that the precise quantification of the gastric cancer progression risk based on the Helicobacter pylori strain genomic data is realized. The application provides a new auxiliary diagnosis and precise intervention tool for the clinic, and the evaluation and prediction accuracy and stability are high.

This invention relates to a humanized Helicobacter pylori cytotoxin-associated protein A monoclonal antibody and its application. The humanized Helicobacter pylori cytotoxin-associated protein A monoclonal antibody includes a heavy chain variable region and a light chain variable region. The nucleic acid sequence of the heavy chain variable region includes CDR1 shown in SEQ ID No. 1 or SEQ ID No. 2, CDR2 shown in SEQ ID No. 3 or SEQ ID No. 4, and CDR3 shown in SEQ ID No. 5 or SEQ ID No. 6. The nucleic acid sequence of the light chain variable region includes CDR1 shown in SEQ ID No. 7 or SEQ ID No. 8, CDR2 with the sequence LVS or KVS, and CDR3 shown in SEQ ID No. 9 or SEQ ID No. 10.

The application belongs to the technical field of biological pharmacy, and discloses a recombinant lactococcus lactis live carrier vaccine, which is obtained by connecting a urease subunit UreA gene with a plasmid expression vector and then electrically transforming the lactococcus lactis; the amino acid sequence of the urease subunit UreA gene is shown as SEQ ID NO. 1. The application further discloses application of the recombinant lactococcus lactis live carrier vaccine in preparation of an anti-helicobacter pylori vaccine. The recombinant lactococcus lactis live carrier vaccine provided by the application can effectively stimulate the body to produce a mucosal immune response and has good protection effect.

A plant-based dispersion composition, a plant-based beverage and a preparation method thereof. The plant-based dispersion composition includes natural dietary fiber, maltitol, oat β-glucan and hawthorn powder; the natural dietary fiber includes seaweed dietary fiber and at least one selected from oat dietary fiber, vegetable dietary fiber and fruit dietary fiber; the seaweed dietary fiber includes fucoidan; the particle size D50 of the plant-based dispersion composition is 5-100 μm. The plant-based beverage of the present invention includes a dispersant and the plant-based dispersion composition stably dispersed in the dispersant, the content of the plant-based dispersion composition is 5-30 wt%, the dispersant includes one or more of deionized water and mineral water. This plant-based beverage is stably dispersed and has a delicate taste. It can be used for gastrointestinal function conditioning, inhibiting Helicobacter pylori adhesion and assisting in protecting the gastric mucosa, improving defecation discomfort and reducing the level of inflammatory factors, while enhancing satiety and making blood glucose release more stable.

The present application relates to a kind of for detecting helicobacter pylori and its preparation method, by weight parts, its raw material includes: urea [ 13 C]10~75 portions, sodium bicarbonate 5~110 portions, lactose 15~45 portions, citric acid 1000~2500 portions, flavoring agent 50~150 portions.The flavoring agent includes at least one of stevioside, sucralose, aspartame, neotame, thaumatin, acesulfame potassium.The present application adopts the way of citric acid and tablet storage separately, effectively solves the problem of flavoring agent addition, avoids the problem of impurity generation due to citric acid addition;At the same time, mannitol is not used in medicine, reduces the risk of patient using medicine.